Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands.
In the Netherlands, the 7-valent pneumococcal conjugate vaccine (PCV-7) was implemented in a 3+1-dose schedule in the national immunization program for infants born after April 1, 2006. To assess the vaccine's effectiveness, we compared disease incidence before and after vaccine implementation (June 2004-June 2006 and June 2006-June 2008, respectively). We serotyped 2,552 invasive pneumococcal isolates from throughout the Netherlands, covering 25% of the country's population. Clinical characteristics were extracted from hospital records. After June 2006, vaccine-serotype invasive pneumococcal disease (IPD) decreased 90% (95% confidence interval [CI] 68%-97%) in children age eligible for PCV-7; simultaneously, however, non-vaccine-serotype IPD increased by 71% (not significant), resulting in a 44% total net IPD reduction (95% CI 7%-66%). IPD rates did not change for other age groups. In the Netherlands, PCV-7 offered high protection against vaccine-serotype IPD in vaccinated children, but increases of non-vaccine-serotype IPD reduced net vaccine benefits.
Rodenburg
Gerwin D
GD
Wilhelmina Children's Hospital/University Medical Center, Utrecht, the Netherlands. g.d.rodenburg@umcutrecht.nl
de Greeff
Sabine C
SC
Jansen
Angelique G C S
AG
de Melker
Hester E
HE
Schouls
Leo M
LM
Hak
Eelko
E
Spanjaard
Lodewijk
L
Sanders
Elisabeth A M
EA
van der Ende
Arie
A
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D002648:Child; D002675:Child, Preschool; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D006801:Humans; D015994:Incidence; D007223:Infant; D008875:Middle Aged; D009426:Netherlands / Q000453:epidemiology; D011008:Pneumococcal Infections / Q000453:epidemiology* / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000627:therapeutic use*; D011159:Population Surveillance; D012703:Serotyping; D013296:Streptococcus pneumoniae / Q000276:immunology / Q000302:isolation & purification; D013997:Time Factors; D016896:Treatment Outcome
D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D022242:Pneumococcal Vaccines
Int J Infect Dis. 2010 Mar;14(3):e197-209
19700359
Commun Dis Intell Q Rep. 2008 Mar;32(1):18-30
18522302
Epidemiol Infect. 2008 Aug;136(8):1096-102
17961282
Euro Surveill. 2009 Mar 26;14(12):
19341605
J Med Microbiol. 2008 Apr;57(Pt 4):480-487
18349369
JAMA. 2005 Oct 26;294(16):2043-51
16249418
J Clin Microbiol. 2009 Apr;47(4):1012-20
19225097
J Infect Dis. 2005 Jul 15;192(2):192-9
15962213
JAMA. 2007 Oct 17;298(15):1772-8
17940232
Clin Infect Dis. 2000 Jan;30(1):122-40
10619741
N Engl J Med. 2009 Jan 15;360(3):244-56
19144940
MMWR Morb Mortal Wkly Rep. 2008 Feb 15;57(6):144-8
18272956
Ned Tijdschr Geneeskd. 2007 Jun 30;151(26):1454-7
17633974
Clin Infect Dis. 2008 Jan 15;46(2):174-82
18171247
Euro Surveill. 2008 Aug 28;13(35):
18761883
Vaccine. 2009 Jun 24;27(31):4136-41
19406190
Pediatr Infect Dis J. 2007 Jun;26(6):468-72
17529860
Vaccine. 2008 Jun 19;26(26):3277-81
18456376
JAMA. 2009 Jul 8;302(2):159-67
19584345
J Clin Microbiol. 2003 Nov;41(11):4966-70
14605125
Eur J Clin Microbiol Infect Dis. 2007 May;26(5):303-10
17457623
N Engl J Med. 2003 May 1;348(18):1737-46
12724479
Vaccine. 2009 Apr 14;27(17):2394-401
19428856
Euro Surveill. 2006 Jun 08;11(6):E060608.2
16819118